Gilead acquires HTI T-cell immunogen HIV vaccines from Barcelona's Aelix Therapeutics for an undisclosed amount. The vaccines ...

After recently discontinuing R&D for Truqap in triple-negative breast cancer, AstraZeneca has some good news on its kinase ...

Replimune announces $125M offering after FDA submission for RP1; Otsuka partners with Ionis on ALS drug ulefnersen; Kanglin Biotechnology raises $20M; Seelos files bankruptcy; Orbus reports positive ...

Former Florida congressman Dave Weldon is President-elect Donald Trump’s pick to lead the CDC, giving Robert F. Kennedy Jr. a ...

The Senate Judiciary Committee narrowly advanced a bill Thursday that would change the way the Patent Trial and Appeal Board ...

Sanofi is proposing a new model for distributing drug discounts under the federal 340B program, according to the Wall Street ...

Eli Lilly and Novo Nordisk have filed dozens of lawsuits against compounding pharmacies marketing their own versions of ...

As the healthcare priorities of President-elect Donald Trump and his HHS pick Robert F. Kennedy Jr. take shape, one idea ...

Novo Nordisk and Viking Therapeutics took to the annual Liver Meeting to make the case for their experimental MASH drugs as ...

Venrock confirmed a new $500 million healthcare fund, separate from its $650 million fund announced in January. The filing ...

Lexicon Pharmaceuticals is reverting to a clinical development company after facing repeated setbacks at the FDA for its type 1 diabetes and chronic kidney disease drug.

Valora Therapeutics has $30 million to jumpstart research on immunotherapies based on sugars — the kind that dots cell ...